临床阶段生物制药公司MRM Health获得5500万欧元B轮融资，支持2b期试验和管道扩展-动脉网

Best-in-Class Experimental Gut Bacteriaased Medicine: MRM Health Lands US$64 Series B

GeneOnline 等信源发布 2025-09-04 14:55



可切换为仅中文







by Bernice Lottering

伯尼丝·洛特林

Share To

分享到

MRM Health lands €55 million in a Series B financing round, anchored by Biocodex and ATHOS, with participation from BNP Paribas Fortis Private Equity and other leading investors.

MRM Health在由Biocodex和ATHOS领投的B轮融资中获得5500万欧元，BNP Paribas Fortis Private Equity和其他主要投资者也参与其中。

elgium-based

比利时的

MRM Health

MRM健康

, a clinical-stage biopharmaceutical company,

，一家临床阶段的生物制药公司，

announced

宣布

the closing of its €55 million (US$64 million) Series B financing. The financing was led by French pharmaceutical group

其 5500 万欧元（6400 万美元）的 B 轮融资的完成。本轮融资由法国制药集团主导。

Biocodex

生物密码公司

with participation from German investor ATHOS, new investor BNP Paribas Fortis Private Equity, and existing backers including SFPIM, Ackermans & van Haaren, OMX Europe Venture Fund, Qbic II, and VIB.

德国投资者ATHOS、新投资者BNP Paribas Fortis私募股权，以及现有支持者包括SFPIM、Ackermans & van Haaren、OMX欧洲风险基金、Qbic II和VIB。

Funding Supports Phase 2b Trial and Pipeline Expansion

资金支持第二b阶段试验和管线扩展

The investment will primarily support a Phase 2b clinical trial for the company’s

该投资将主要用于支持公司进行的 Phase 2b 期临床试验，

lead candidate

领先候选人

, MH002—a rationally designed live microbial consortium therapy for ulcerative colitis. Phase 2a trials previously demonstrated MH002’s safety and efficacy in both ulcerative colitis and pouchitis. MRM Health will also advance two additional microbiome-based programs toward IND approval, targeting chronic inflammation and improving immune-oncology outcomes.

MH002——一种合理设计的用于治疗溃疡性结肠炎的活微生物联合疗法。二期a阶段试验先前已证明MH002在溃疡性结肠炎和回肠袋炎中的安全性和有效性。MRM Health还将推动另外两个基于微生物组的项目走向新药临床试验申请（IND），目标是针对慢性炎症并改善免疫肿瘤学结果。

The company plans to forge .

公司计划打造。

strategic partnerships across human and animal health

在人类和动物健康领域的战略伙伴关系

to broaden its therapeutic portfolio.

拓宽其治疗组合。

MH002 represents one of the most advanced microbiome-based therapies in development for inflammatory bowel disease. The candidate combines six carefully selected bacterial strains, engineered to counter key disease pathways and remain stable in the gut. Early Phase 2a studies

MH002代表了针对炎症性肠病开发的最先进的微生物组疗法之一。该候选药物结合了六种精心挑选的细菌菌株，经过工程设计以对抗关键的疾病通路并在肠道中保持稳定。早期的2a期研究

confirmed

确认

it was safe and hinted at clinical benefit in both ulcerative colitis and pouchitis. Built on MRM Health’s CORAL® platform, the therapy benefits from a unique manufacturing process that produces the full bacterial consortium as a single drug product, enabling consistency at scale and improving both regulatory prospects and patient usability..

它在溃疡性结肠炎和回肠袋炎中均表现出安全性和潜在的临床益处。该疗法基于MRM Health的CORAL®平台，通过独特的生产工艺将完整的细菌群落制成单一药物产品，从而实现规模化的一致性，同时提升了监管前景和患者使用的便利性。

Strategic Collaboration with Biocodex

与Biocodex的战略合作

As part of the funding package, MRM Health will collaborate with Biocodex—a microbiota research pioneer for more than 70 years—to enhance development and scalable manufacturing capabilities for live biotherapeutics. This collaboration includes non-dilutive funding that will strengthen MRM Health’s operational resilience..

作为资金配套计划的一部分，MRM Health将与拥有70多年微生物组研究经验的先驱企业Biocodex合作，以增强活体生物治疗产品的开发和规模化生产能力。此次合作包括非稀释性资金支持，这将加强MRM Health的运营韧性。

MRM Health CEO Sam Possemiers described the financing as pivotal: “With the support of an experienced international syndicate, we are positioned to deliver transformative therapies for chronic inflammatory diseases, where current treatments often fall short.”

MRM Health首席执行官Sam Possemiers将此次融资描述为关键转折点：“在经验丰富的国际财团支持下，我们有能力提供针对慢性炎症性疾病的变革性疗法，而当前的治疗方案往往效果不足。”

Biocodex CEO Nicolas Coudurier underlined the strategic synergy: “By combining Biocodex’s long-standing leadership in microbiota with MRM Health’s breakthrough platform, we aim to deliver meaningful solutions for patients worldwide.”

Biocodex首席执行官尼古拉斯·库杜里埃强调了战略协同作用：“通过将Biocodex在微生物群领域的长期领导地位与MRM Health的突破性平台相结合，我们旨在为全球患者提供有意义的解决方案。”

Other investors echoed their confidence in MRM Health’s technological maturity and scalability.

其他投资者也对MRM Health的技术成熟度和可扩展性表示了信心。

Ulcerative Colitis in Context

溃疡性结肠炎的背景

Ulcerative colitis is a chronic autoimmune inflammatory bowel disease (IBD) that affects

溃疡性结肠炎是一种慢性自身免疫性炎症性肠病 (IBD)，它影响

up to 10 million people worldwide

全世界多达1000万人

, with cases rising steadily. The condition causes recurring flares of debilitating diarrhea, abdominal pain, rectal bleeding, and fatigue, often disrupting daily life. Despite existing treatments, most therapies only suppress inflammation rather than address underlying drivers of disease. Patients still face a .

，病例数量持续上升。该疾病会导致反复发作的严重腹泻、腹痛、便血和疲劳，常常扰乱日常生活。尽管已有治疗方法，但大多数疗法仅能抑制炎症，而无法解决疾病的潜在诱因。患者仍然面临。

10–15%

10%-15%

cumulative

累积的

risk

风险

of colectomy within a decade, underscoring the need for more effective and durable options.

在十年内进行结肠切除术，突显了对更有效和持久方案的需求。

The early clinical studies suggest MH002 may offer a new therapeutic approach. In a Phase 2a

早期的临床研究表明，MH002可能提供一种新的治疗方法。在2a期

trial

试验

in ulcerative colitis, the therapy was safe and well tolerated and showed early efficacy: 18% of patients achieved remission at eight weeks, compared with none on placebo, alongside reduced inflammation markers. In a parallel study in pouchitis, MH002 produced a 46% remission rate at week eight, with notable improvements in symptom scores and mucosal healing..

在溃疡性结肠炎中，该疗法安全且耐受性良好，并显示出早期疗效：18%的患者在八周时达到缓解，而安慰剂组无一例缓解，同时炎症标志物减少。在一项针对贮袋炎的平行研究中，MH002在第八周达到了46%的缓解率，症状评分和黏膜愈合均有显著改善。

ORAL® Platform and Manufacturing Edge

ORAL®平台与制造优势

MRM Health’s

MRM Health的

CORAL® platform

CORAL® 平台

designs microbial consortia—carefully selected bacterial strains that act together to target disease pathways more effectively than single-strain approaches. The platform uses bioinformatics, optimization tools, and a human gut simulator (SHIME®) to identify and refine strains for potency, resilience, and stable engraftment in the gut.

设计微生物联合体——精心挑选的菌株，它们协同作用，比单菌株方法更有效地靶向疾病通路。该平台利用生物信息学、优化工具和人体肠道模拟器 (SHIME®) 来识别和优化菌株，以提高其效力、适应力以及在肠道中的稳定定植能力。

Its most advanced product, MH002, is a six-strain consortium developed for inflammatory bowel disease. While the company has not publicly disclosed the exact bacterial identities, it describes them as well-characterized commensal strains with butyrate-producing, immune-modulating, and mucosal-healing properties.

其最先进的产品MH002是为治疗炎症性肠病开发的六菌株组合。尽管该公司尚未公开披露确切的细菌身份，但描述它们为具有产丁酸、免疫调节和黏膜修复特性的经过充分研究的共生菌株。

Preclinical studies demonstrated that this combination can restore epithelial barrier integrity, control inflammation, and promote tissue repair..

临床前研究显示，这种组合可以恢复上皮屏障的完整性、控制炎症并促进组织修复。

A key feature of CORAL® lies in its single-substance manufacturing process. Instead of growing strains separately and mixing them afterward, the platform produces the entire consortium as one standardized drug substance under cGMP conditions. This approach enhances reproducibility and quality control, simplifies regulatory pathways, and ensures each patient receives consistent dosing..

CORAL® 的一个关键特征在于其单一物质的制造过程。该平台不是分别培养菌株然后再将其混合，而是在 cGMP 条件下将整个菌群作为单一标准化药物成分进行生产。这种方法提高了可重复性和质量控制，简化了监管路径，并确保每位患者获得一致的剂量。

As part of the financing, Jean‑Patrick Hennebelle (Biocodex), Julian Zachmann (ATHOS), and Goedele Ertveldt (SFPIM) will join MRM Health’s board of directors—further strengthening governance as the company moves into late-stage clinical development.

作为融资的一部分，Jean‑Patrick Hennebelle（Biocodex）、Julian Zachmann（ATHOS）和Goedele Ertveldt（SFPIM）将加入MRM Health的董事会，这将进一步加强公司治理，因为该公司正进入晚期临床开发阶段。

Market Context: Other Players in Microbiome and IBD Therapeutics

市场背景：微生物组和IBD治疗领域的其他参与者

To situate MRM Health’s progress within the broader landscape, here’s a snapshot of notable competitors and developments:

为了在更广阔的背景下定位MRM Health的进展，以下是值得注意的竞争对手和发展概况：

Abivax

阿比瓦克斯

made headlines in August 2025 when its oral candidate

2025年8月，其口服候选药物成为头条新闻

obefazimod

奥贝法佐莫德

delivered successful Phase III results in ulcerative colitis, sending the company’s stock

在溃疡性结肠炎的三期临床试验中取得了成功结果，推动了公司股票上涨

soaring by over 580%

飙升超过580%

。

Roche

罗氏

is advancing its monoclonal antibody

正在推进其单克隆抗体

afimkibart

阿菲姆基巴特

(targeting TL1A),

（靶向TL1A），

now in

现在在

Phase III trials for ulcerative colitis and Phase II for Crohn’s and atopic dermatitis.

溃疡性结肠炎的 III 期试验，克罗恩病和特应性皮炎的 II 期试验。

Microbiotica

微生物组学

recently completed recruitment for its

近期完成了其

Phase 1b trial

第1b阶段试验

的

MB310

, a precision live biotherapeutic for ulcerative colitis, leveraging defined microbial strains.

，一种针对溃疡性结肠炎的精准活体生物治疗药物，利用明确的微生物菌株。

Seres Therapeutics

Seres 治疗学

continues

继续

exploring

探索

live biotherapeutics in inflammatory and immune-related disease areas, with R&D partnerships advancing their investigational candidates.

炎症和免疫相关疾病领域的活体生物治疗药物，通过研发合作推进其研究中的候选药物。

BiomeBank

生物群系库

develops

开发

cultured microbiome therapies, including

培养的微生物组疗法，包括

BB265

, targeted at ulcerative colitis and backed by a track record in donor-derived microbiome therapeutics.

，针对溃疡性结肠炎，并且在供体衍生的微生物组疗法方面有着良好的记录支持。

According to

根据

pipeline analysis

管道分析

, over

，结束

140 companies and 180 microbiome disease therapies

140家公司和180种微生物组疾病疗法

are in active development, including SSR platforms from

正在积极开发中，包括来自的SSR平台

MaaT Pharma, Seres

MaaT制药，Seres

，

Vedanta

韦丹塔哲学

，

Enterome

肠智组

, and

，以及

Microbiotica

微生物群

。

In parallel, conventional non-microbiome therapeutics are advancing:

与此同时，传统的非微生物组疗法正在取得进展：

Teva/Sanofi’s duvakitug

Teva/Sanofi的duvakitug

(a TL1A inhibitor)

（一种TL1A抑制剂）

produced

生产

“best‑in‑class” Phase 2 results in ulcerative colitis, spurring significant market interest and a push toward Phase 3.

“同类最佳”二期溃疡性结肠炎结果，激发了市场极大兴趣，并推动进入三期临床试验。

Eli Lilly

礼来公司

acquired

获得的

Morphic Holding

形态控股

for $3.2 billion, gaining access to

以 32 亿美元的价格，获得了访问权限

MORF‑057

, now in mid‑stage trials for ulcerative colitis and Crohn’s disease.

，目前正在进行溃疡性结肠炎和克罗恩病的中期试验。

Looking Ahead in the Microbiome Race

展望微生物组竞赛的未来

MRM Health’s €55 million Series B round places the company firmly among the leading contenders in the microbiome therapeutics field. The investment not only validates the potential of its CORAL® platform but also underscores investor confidence in microbiome-based strategies as a complement—or possible alternative—to biologics and small molecules that dominate inflammatory disease treatment today..

MRM Health公司5500万欧元的B轮融资使其稳居微生物组治疗领域的领先竞争者之列。这项投资不仅验证了其CORAL®平台的潜力，还凸显了投资者对基于微生物组策略的信心，这种策略可作为当今主导炎症性疾病治疗的生物制品和小分子药物的补充，甚至可能成为替代方案。

While competition is intensifying, from start-ups developing live biotherapeutics to large pharmaceutical companies testing next-generation antibodies and oral drugs, MRM Health’s ability to

随着竞争的加剧，从开发活体生物治疗剂的初创公司到测试下一代抗体和口服药物的大型制药公司，MRM Health 的能力

design, optimize, and manufacture full microbial consortia at scale

设计、优化并大规模制造完整的微生物群落

may set it apart. If its Phase 2b trial confirms early clinical promise, the company could play a defining role in shaping how microbiome-based medicines transition from experimental therapies to mainstream treatment options.

可能使其与众不同。如果其2b期试验确认了早期的临床潜力，这家公司可能在塑造基于微生物组的药物从实验性疗法过渡到主流治疗选择方面发挥决定性作用。